Results showed significant expansion of mesenchymal progenitors (CD90؉, CD105؉, and CD166؉) in each TRC formulation. In vivo bone formation, measured by histology, was highest in the TRC group, followed by TRC-C Ad and TRC-C. The TRC product outperformed starting BM MNC and had equivalent bone forming potential to purified MSCs at the same cell dose. Post hoc analysis revealed that the presence of CD90؉, CD105؉, and CD166؉ correlated strongly with in vivo bone formation scores (r 2 > .95). These results demonstrate that this bioreactor system can be used to generate, in a single step, a population of progenitor cells with potent osteogenic potential.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.